MEET THOMAS At Travere Therapeutics, We Are In Rare For Life. MEET LILLIE We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. PATIENTS & CAREGIVERS On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. PIPELINE MEET TIFFANY We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow. PATIENT ADVOCACY MEET PAUL We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. OUR THERAPIES Therapeutic Areas These are the conditions for which we have an approved therapy or a research and development program. Peroxisomal Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD) Cerebrotendinous Xanthomatosis (CTX) Cystinuria Bile Acid Synthesis Disorders (BASD) Focal Segmental Glomerulosclerosis (FSGS) IgA Nephropathy (IgAN) Classical Homocystinuria (HCU) Alagille Syndrome (ALGS) N-Glycanase 1 (NGLY1) Deficiency We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder. Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021 SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021. Read the full press release > Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2021 financial results and provided a corporate update. Read the full press release > Jamela Diagnosed at birth with homocystinuria, Jamela reflects on what it was like growing up with this rare metabolic condition, and how her family continues to be a source of strength. Benji Benji, nine years old, loves wrestling with his father and playing with his best friends. He is quite fond of elevators – both watching them and riding in them. Benji is a happy kid. He is also a rare kid, and lives with NGLY1 deficiency, a complex neurological syndrome resulting from a shortage of the enzyme N-glycanase 1. Read about Benji’s ultrarare journey, Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal Phase 3 clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease. There are currently no approved medicines indicated for FSGS or IgAN. Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the U.S. and Europe. Read the full press release > Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations. Read the full press release > VIEW MORE PATHFINDER STORIES © 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company. Terms and Conditions | Privacy Policies | Cookie Preferences This website uses cookies for optimal site functionality. By continuing to use this website, you consent to our use of cookies. To change your cookie preferences, click on "Cookie Settings" or for more information, please see ourPrivacy Policies. Accept All Cookies Cookie Settings